Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Toremifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 12/20 | 0.91 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 0.79 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ESRRG | P62508 | 13/20 | 0.91 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | PGR | P06401 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | ESRRA | P11474 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | EGFR | P00533 | 1/20 | 0.74 |
| ▸ | GBA1 | P04062 | 1/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toremifene SCHEMBL1152000 | 1.00 | HTR6 (1.00) | HTR6LMNAESRRGESR1ESR2 | |
| Toremifene SCHEMBL906278 | 1.00 | HTR6 (1.00) | HTR6LMNAESRRGESR1ESR2 | |
| Toremifene SCHEMBL2223880 | 0.99 | HTR6 (0.97) | HTR6LMNAESRRGESR1ESR2 | |
| SCHEMBL5739474 | 0.95 | HTR6 (0.91) | HTR6LMNAESRRGESR1ESR2 | |
| SCHEMBL5736471 | 0.95 | HTR6 (0.91) | HTR6LMNAESRRGESR1ESR2 | |
| SCHEMBL5739418 | 0.95 | HTR6 (0.91) | HTR6LMNAESRRGESR1ESR2 | |
| 4-Hydroxytormifene SCHEMBL9099337 | 0.95 | ESR1 (1.00) | HTR6LMNAESRRGESR1ESR2 | |
| SCHEMBL5736463 | 0.95 | HTR6 (0.91) | HTR6LMNAESRRGESR1ESR2 | |
| SCHEMBL5737155 | 0.95 | HTR6 (0.91) | HTR6LMNAESRRGESR1ESR2 | |
| 4-Hydroxytormifene SCHEMBL906309 | 0.95 | ESR1 (1.00) | HTR6LMNAESRRGESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 75073 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2026098706-A1 | USE IN TREATING BREAST CANCER AFTER TREATMENT WITH CDK4/6 INHIBITOR | 正大天晴药业集团股份有限公司 | 2026-05-15 | — | — | WO | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| CN-122029214-A | Phospholipid drug conjugate and preparation method and application thereof | 上海弼领生物技术有限公司 | 2026-05-12 | — | — | CN | claimed |
| WO-1994012162-A1 | SYNDECAN STIMULATION OF CELLULAR DIFFERENTIATION | WAERRI ANNI MAIJA (FI) | 1994-06-09 | — | — | WO | claimed |
| WO-1994009764-A1 | USE OF NON STEROIDAL ANTI ESTROGENS FOR AUTOIMMUNE DISEASES | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1994-05-11 | — | — | WO | claimed |
| WO-1993019746-A1 | TOPICAL ADMINISTRATION OF TOREMIFENE AND ITS METABOLITES | Orion-Yhtymä Oy (FI) | 1993-10-14 | — | — | WO | claimed |
| EP-0551434-A1 | HIGH AFFINITY TAMOXIFEN DERIVATIVES AND USES THEREOF. | UNIV TEXAS (US) | 1993-07-21 | — | — | EP | claimed |
| WO-1993011757-A1 | DRUG FORMULATIONS FOR PARENTERAL USE | Orion-Yhtymä Oy (FI) | 1993-06-24 | — | — | WO | claimed |
| EP-0526608-A1 | THERAPEUTIC AGENTS FOR THE TREATMENT OF MULTIDRUG RESISTANCE TO CANCERS. | DEBIOPHARM SA (CH) | 1993-02-10 | — | — | EP | claimed |
| WO-1992014467-A1 | THERAPEUTIC AGENTS FOR THE TREATMENT OF MULTIDRUG RESISTANCE TO CANCERS | DEBIOPHARM S.A. (CH) | 1992-09-03 | — | — | WO | claimed |
| WO-1992006068-A1 | HIGH AFFINITY TAMOXIFEN DERIVATIVES AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-04-16 | — | — | WO | claimed |
| EP-0415623-A2 | Toremifene or demethyltoremifene as hydroxytoremifene for the reversal of multidrug restistance of cancer cells against cytotoxic drugs | ORION-YHTYMÀ OY (FI) | 1991-03-06 | — | — | EP | claimed |
| US-4990538-A | Administering for the treatment of cancer | ORION CORPORATION (FI) | 1991-02-05 | — | — | US | claimed |